-
公开(公告)号：US20180119104A1
公开(公告)日：2018-05-03
申请号：US15835850
申请日：2017-12-08
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor Slukvin , Akhilesh Kumar
CPC classification number: C12N5/0661 , A61K35/28 , A61K35/34 , A61K35/44 , C12N2500/90 , C12N2501/11 , C12N2501/115 , C12N2501/135 , C12N2501/15 , C12N2501/165 , C12N2501/999 , C12N2506/02 , C12N2506/1346 , C12N2506/45
Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.
-
公开(公告)号：US11345895B2
公开(公告)日：2022-05-31
申请号：US15816914
申请日：2017-11-17
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor I. Slukvin , Mi Ae Park , Akhilesh Kumar
IPC: A61K35/17 , C12N5/071 , C07K14/705 , C12N5/0789 , C12N5/0783 , C07K14/47 , A61K35/12
Abstract: The present invention is a method of creating a population of hemogenic endothelial cells with arterial specification and enhanced T cell potential. In one embodiment, the method uses ETS transgene induction at the mesodermal stage of differentiation. In another embodiment, the method activates ERK and NOTCH signaling at the mesodermal stage of differentiation.
-
公开(公告)号：US11091738B2
公开(公告)日：2021-08-17
申请号：US15835850
申请日：2017-12-08
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor Slukvin , Akhilesh Kumar
Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.
-
公开(公告)号：US20180142207A1
公开(公告)日：2018-05-24
申请号：US15816914
申请日：2017-11-17
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor I. Slukvin , Mi Ae Park , Akhilesh Kumar
IPC: C12N5/071 , A61K35/17 , C07K14/705 , C12N5/0789 , C12N5/0783
CPC classification number: C12N5/069 , A61K35/17 , A61K2035/124 , C07K14/4702 , C07K14/70503 , C12N5/0636 , C12N5/0647 , C12N2501/42 , C12N2501/60 , C12N2501/602 , C12N2501/727 , C12N2506/02 , C12N2506/28 , C12N2506/45 , C12N2510/00
Abstract: The present invention is a method of creating a population of hemogenic endothelial cells with arterial specification and enhanced T cell potential. In one embodiment, the method uses ETS transgene induction at the mesodermal stage of differentiation. In another embodiment, the method activates ERK and NOTCH signaling at the mesodermal stage of differentiation.
-
公开(公告)号：US20250145958A1
公开(公告)日：2025-05-08
申请号：US18819158
申请日：2024-08-29
Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventor： Igor Slukvin , Akhilesh Kumar
Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitor, and methods and compositions for clinical applications in the field of regenerative medicine.
-
Patent Agency Ranking
公开(公告)号：US12098390B2
公开(公告)日：2024-09-24
申请号：US17403202
申请日：2021-08-16
Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventor： Igor Slukvin , Akhilesh Kumar
CPC classification number: C12N5/0661 , A61K35/34 , A61K35/44 , A61K35/28 , C12N2500/90 , C12N2501/11 , C12N2501/115 , C12N2501/135 , C12N2501/15 , C12N2501/165 , C12N2501/999 , C12N2506/02 , C12N2506/1346 , C12N2506/45
Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.
-
7.发明公开公开(公告)号：US20240191189A1
公开(公告)日：2024-06-13
申请号：US18537479
申请日：2023-12-12
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor Slukvin , Akhilesh Kumar , Saritha Sandra D'Souza
IPC: C12N5/0783 , C12N5/0781
CPC classification number: C12N5/0636 , C12N5/0635 , C12N2506/45 , C12N2510/00 , C12N2513/00
Abstract: The present disclosure provides reagents and methods for producing arterial hemogenic endothelium, hematopoietic progenitor, and lymphoid cell cultures. Pharmaceutical compositions comprising arterial hemogenic endothelium cells, hematopoietic progenitor cells, and lymphoid cells produced by the reagents and methods of the invention and therapeutic methods using these pharmaceutical compositions are also provided.
-
公开(公告)号：US20210380947A1
公开(公告)日：2021-12-09
申请号：US17403202
申请日：2021-08-16
Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventor： Igor Slukvin , Akhilesh Kumar
Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.
-
公开(公告)号：US20140369968A1
公开(公告)日：2014-12-18
申请号：US14303428
申请日：2014-06-12
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor Slukvin , Akhilesh Kumar
CPC classification number: C12N5/0661 , A61K35/28 , A61K35/34 , A61K35/44 , C12N2500/90 , C12N2501/11 , C12N2501/115 , C12N2501/135 , C12N2501/15 , C12N2501/165 , C12N2501/999 , C12N2506/02 , C12N2506/1346 , C12N2506/45
Abstract: The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.
Abstract translation: 本发明一般涉及用于治疗性血管组织工程的方法和组合物。 特别地，本发明提供从人间充质祖细胞产生基本上纯的血管生成细胞群的方法，以及用于再生医学领域临床应用的方法和组合物。
-
公开(公告)号：US20220306988A1
公开(公告)日：2022-09-29
申请号：US17827338
申请日：2022-05-27
Applicant: Wisconsin Alumni Research Foundation
Inventor： Igor I. Slukvin , Mi Ae Park , Akhilesh Kumar
IPC: C12N5/071 , A61K35/17 , C07K14/705 , C12N5/0789 , C12N5/0783 , C07K14/47
Abstract: The present invention is a method of creating a population of hemogenic endothelial cells with arterial specification. In one embodiment, the method uses ETS transgene induction at the mesodermal stage of differentiation. In another embodiment, the method activates ERK signaling at the mesodermal stage of differentiation.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.015 seconds)
